A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC)

摘要: 4563 Background: Single-agent taxanes have demonstrated clinical activity in HPRC; however, the median duration of response is relatively short. The epothilone EPO906 a potent microtubule stabilizer that not substrate for multidrug-resistance protein and has cytotoxic taxane-sensitive, -resistant, refractory tumors. Thus, may be an appropriate alternative to taxane therapy patients (pts) with HRPC. In phase IIa study, we investigated safety efficacy weekly these pts. Methods: Pts histologically proven disease documented metastases or prostate-specific antigen (PSA) progression > 20 ng/mL were enrolled. could received ≤ 1 prior chemotherapy regimen hormone-resistant disease. maintained on androgen ablation had undergone orchiectomy. 2.5 mg/m2 was administered via 5-min IV infusion once 3 wks followed by wk rest 6 cycles. Results: A total 37 pts ...